Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review. (PubMed, Diabetes Metab Syndr Obes) - Oct 1, 2026 - "The review encompassed glucagon-like peptide-1 receptor agonists (GLP-1 RA), including semaglutide, liraglutide, exenatide, and orforglipron; multi-receptor incretin agonists, including tirzepatide, retatrutide, and survodutide; amylin-based combination therapy (cagrilintide plus semaglutide); established non-incretin AOMs (orlistat, phentermine, phentermine/topiramate, and naltrexone/bupropion); microbiome-targeted therapies; and nutraceutical-based interventions. Overall, incretin-based therapies currently provide the greatest weight-loss benefit, although evidence for several emerging pharmacotherapies, microbiome-targeted therapies, and nutraceutical-based interventions remains limited. Further well-designed comparative trials, mechanistic studies, and long-term real-world investigations are needed to better establish the durability, safety, and clinical applicability of emerging AOMs."
Journal • Review • Genetic Disorders • Obesity
|
|
Alifa Nisa Deliyana; Dimas Setyadi Putra; Irma Melyani Puspitasari; Lily Indriani Octovia; Nurqisthi Iqlima Adiputri; Rano Kurnia Sinuraya; Sekar Ayu Paramita
|